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Abstract
Aims/hypothesis This study aimed to explore the infancy growth trajectories of ‘recent’ and ‘earlier’ offspring of mothers with
gestational diabetes mellitus (OGDM), each compared with the same control infants, and investigate whether ‘recent’ OGDM
still exhibit a classical phenotype, with macrosomia and increased adiposity.
Methods Within a prospective observational birth cohort, 98 ‘earlier’OGDMborn between 2001 and 2009 were identified using
75 g oral glucose tolerance testing at 28 weeks gestation, 122 recent OGDM born between 2011 and 2013 were recruited
postnatally through antenatal diabetes clinics, and 876 normal birthweight infants of mothers with no history of diabetes were
recruited across the full study period as the control group. All infants followed the same study protocol (measurements at birth, 3,
12 and 24 months, including weight, length and skinfold thickness indicating adiposity, and detailed demographic data). In all
cases, GDM was defined using the International Association of Diabetes and Pregnancy Study Group criteria.
Results Earlier OGDM had higher birthweight SD scores (SDS) than control infants. Conversely, recent OGDM had similar
birthweight- and length SDS to control infants (mean ± SD, 0.1 ± 1.0 and− 0.1 ± 0.9, respectively), but lower mean skinfold
thickness SDS (−0.4 ± 0.6 vs 0.0 ± 0.9; p < 0.001). After birth, earlier OGDM showed reduced gains in weight and length
between 3 and 12 months. In contrast, recent OGDM had increased weight and skinfold thickness gains until 3 months, followed
by reduced gains in those variables from 3 to 12 months, compared with control infants. At 24 months, recent OGDM had lower
adiposity than control infants (mean skinfold thickness SDS −0.3 ± 0.7 vs 0.0 ± 0.8; p < 0.001). At all time points recent OGDM
had lower growth measurements than earlier OGDM.
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Conclusions/interpretation Recent OGDM showed different growth trajectories to the earlier group, namely normalisation of
birthweight and reduced adiposity at birth, followed by initial rapid weight gain but subsequent reduced adiposity postnatally.
While avoidance of macrosomia at birth may be advantageous, the longer-term health implications of these changing growth
trajectories are uncertain.
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Abbreviations
CBGS Cambridge Baby Growth Study
GDM Gestational diabetes mellitus
HAPO Hyperglycemia and Adverse
Pregnancy Outcomes
IADPSG International Association of Diabetes
and Pregnancy Study Groups
IMD Index of Multiple Deprivation
MiG trial Metformin in Gestational Diabetes trial
OGDM Offspring of gestational diabetic mother
SDS SD score
SGA Small for gestational age
Introduction
Offspring of gestational diabetic mothers (OGDM) are at in-
creased risk of macrosomia [1] and higher newborn adiposity
[2]. These physical traits are associated with obstetric and neo-
natal complications, including prematurity, shoulder dystocia,
hypoglycaemia and jaundice [3]. Subsequently, OGDM demon-
strate a relatively slow weight gain or ‘catch-down’ growth until
2 years of age [4, 5]. Weight gain is then accelerated after age
5 years [6] and linked to long-term increased metabolic risks,
including obesity and type 2 diabetes [7–9]. However, in recent
years, some studies suggest that birth size of OGDM may be
normalising [10, 11].
This could be attributed to the changing diagnostic criteria for
gestational diabetes mellitus (GDM) and subsequent more inten-
sive management of gestational hyperglycaemia. In 2010, the
International Association of Diabetes and Pregnancy Study
Groups (IADPSG) suggested more stringent GDM diagnostic
criteria than those used previously [12]. This followed results
from the Hyperglycemia and Adverse Pregnancy Outcomes
(HAPO) study, involving 23,000 non-GDM pregnant women
across nine countries. The study found that maternal blood
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glucose was positively correlated with increased birthweight,
cord blood C-peptide level, neonatal hypoglycaemia and
Caesarean section delivery rates [13, 14]. Even before the imple-
mentation of these guidelines, several recent randomised con-
trolled trials had shown decreased perinatal complications and
more normal birthweights after intensive treatment of glucose
intolerance in pregnancy (dietary advice, glucose monitoring,
and insulin as needed), compared with routine pregnancy care
[15–17]. The introduction of the IADPSG guidelines may lead
to more mothers being treated and perhaps more intensively. The
impact of these temporal changes inmanagement on early infancy
growth has not been documented. As well as large birthweight,
low birthweight and rapid postnatal ‘catch-up’ growth may also
have implications for future health [18].
We hypothesised that recent changes in the detection andman-
agement of GDM could have an impact on classical growth dif-
ferences long-observed between OGDM and other infants.
Within the context of an established prospective birth cohort,
we retrospectively applied the 2010 IADPSG criteria to two
groups of OGDM born in non-overlapping years and compared
birth size and early infancy anthropometry in each group, against
a control group unaffected by GDM.
Methods
Study population and design The Cambridge Baby Growth
Study (CBGS) has been recruiting newborns at the Rosie
Maternity Hospital, Cambridge, UK for the study of pregnan-
cy and postnatal determinants of early infancy growth and
metabolism since 2001 [19]. Between 2001 and 2009 mothers
were approached during pregnancy and all underwent a for-
mal 75 g OGTT at 28 weeks gestation as part of a research
protocol. The fasting and 2 h glucose results were fed back to
guide clinical management.
Between 2011 and 2013, in addition to the recruitment of
women with uncomplicated pregnancies, we specifically re-
cruited mothers identified as having GDM from specialist
antenatal clinics who had undergone a 50 g glucose challenge
test followed by a formal OGTT.
For the purpose of the current analyses, the same IADPSG
criteria were retrospectively applied both to thoseOGTTcollected
as part of research between 2001 and 2009 and to those carried
out as part of the clinical diagnostic procedures between 2011 and
2013 in order to reduce any bias in severity of GDM resulting
from changing diagnostic criteria over this period.
The retrospective application of the IADPSG criteria has
implications for treatment as 19% of the ‘earlier’ OGDM
group were not diagnosed and did not receive any treatment.
Inclusion criteria To select mothers with GDM for study of both
cohorts (‘earlier’ and ‘recent’), IADPSG criteria [12] (at least one
glucose concentration on a 75 g OGTT at around 28 weeks
gestation: >5.1 mmol/l at 0 min, >10.0 mmol/l at 60 min,
>8.5 mmol/l at 120 min) were applied retrospectively to the
earlier cohort and prospectively in the recent OGDM group,
allowing comparable earlier and recent OGDM subgroups. In
all subgroups, the following additional criteria were met: single-
ton pregnancy; no significant maternal comorbidity (such as pre-
eclampsia, hypertension, antiphospholipid syndrome, ankylosing
spondylitis, lupus or ulcerative colitis); gestational age
≥36 weeks. Cases of maternal type 1 or type 2 diabetes and
infants with a genetic or syndromal disease were excluded.
GDM populations The earlier OGDM (N = 98) were born be-
tween 2001 and 2009 and the recent OGDM (N = 122) were
born between 2011 and 2013.
In the earlier OGDM population, a 75 g OGTT at 28 weeks
gestation was performed as part of the research protocol and, for
the purpose of the current study, the IADPSG criteria were ap-
plied retrospectively. In contrast, the clinical decision to treat
these women in the earlier GDM cohort was broadly based on
the WHO 1999 guideline [20], which considers fasting and 2 h
glucose values (but not 1 h glucose). Based on available records
and information from treating clinicians, GDMwas mostly treat-
ed with diet and lifestyle modification, with or without insulin;
metformin was not routinely used at that time.
In the recent OGDM population, women were recruited
from the antenatal GDM clinic following routine practice (a
75 g OGTT in high-risk women and those identified through a
universal 50 g glucose challenge at 24–26 weeks as a neces-
sary prerequisite for the woman to undergo glucose tolerance
testing). All women received standardised dietary and lifestyle
advice, and were seen in clinic regularly (on average every
2 weeks). Additionally, metformin and/or insulin were pre-
scribed as required, guided by regular fasting and postprandial
glucose monitoring.
Control population A CBGS control population (N = 876)
was comprised of mother–infant dyads with normal blood
glucose levels on OGTT at 28 weeks using the IADPSG
criteria between 2001 and 2009 (and those recruited later
who had normal 50 g glucose challenge tests). They were
studied using the identical postnatal research protocol.
Studies were approved by the Cambridge local research ethics
committee, and all mothers gave informed written consent.
Birth measurements and infancy anthropometry Infants’
birthweights were obtained from hospital records. Newborn
(within first 8 days) length and skinfold thickness, and subse-
quent measurements at 3, 12 and 24 months of age were per-
formed by three trained paediatric research nurses, using iden-
tical protocols for all cohorts. Weight was measured to the
nearest 1 g using a Seca 757 electronic baby scale (Seca,
Birmingham, UK). Length was measured to the nearest
0.1 cm using an Infantometer (Seca 416). Skinfold thickness
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was measured in triplicate at four sites (triceps, subscapular,
flank, quadriceps) on the left side of the body using a Holtain
Tanner/Whitehouse Skinfold Caliper (Holtain, Crymych,
UK).
Statistical analyses Infancy age- and sex-appropriate SD scores
(SDS)were calculated for weight and lengthmeasurements (with
adjustment for gestational age at birth and 3 months), by com-
parison with the UK 1990 growth reference using LMS growth
software [21]. For each of the four skinfold thickness measure-
ments an internal SDS was calculated, using residuals from a
linear regression model, adjusting for infancy age, (gestational
age at birth and 3months) and sex.Mean skinfold thickness SDS
was used in analyses. Maternal BMI was derived from self-
reported pre-pregnancy weight divided by the square of mea-
sured height (kg/m2). Birth ponderal index was calculated by
dividing the infant’s birthweight by its birth length cubed (kg/
m3). Deprivation was assessed using an integrated index based
on residential postcodes [22].
Maternal and birth characteristics were compared between
groups using ANOVA with Bonferroni post hoc analysis for
continuous variables, and χ2 tests for categorical outcomes.
Unless otherwise stated, all data are presented as means ± SDs.
Multiple linear regression was used to investigate the effect
of GDM on birth outcomes, allowing adjustment for potential
confounders, including infant sex, postnatal age, gestational
age, pre-pregnancy maternal BMI, maternal height, parity,
breastfeeding history at 3 months, delivery method, maternal
ethnicity, socioeconomic status reflected by Index of Multiple
Deprivation (IMD) and pregnancy smoking history. All con-
founders were chosen a priori through the extensive work of
CBGS and the Avon Longitudinal Study of Parents and
Children (ALSPAC) [18].
Under the traditional listwise deletion method, only
68% of the control group and 64% of both recent and
earlier OGDM had complete data on all covariates.
Covariates with most missing values were maternal pre-
pregnancy BMI for control infants and ‘earlier OGDM’,
and smoking history for recent OGDM. Data were primar-
ily missing due to incomplete perinatal questionnaire re-
sponses. Missing covariates including IMD (n = 3), parity
(n = 4), maternal ethnicity (n = 8), smoking history during
pregnancy (n = 39), maternal pre-pregnancy BMI (n =
185), maternal height (n = 148), delivery method (n = 27)
and infant feeding history (n = 189) were imputed under
the assumption that they are missing at random. The R
package ‘Multiple Imputations via Chained Equations
(MICE)’ was used to generate 20 imputed datasets, using
normal linear regression for continuous variables and lo-
gistic linear regression for binary variables. Analyses run
on each dataset were pooled according to Rubin’s rules
[23]. Imputed values compared reasonably to observed
values, and the results (i.e. linear regression model on birth
data, Table 2) using listwise deletion were similar to im-
puted values, therefore imputed values were presented in
the subsequent analyses.
In the visit measurements, missing data were commonly
due to loss-to-follow-up or drop outs. In order to capitalise
the longitudinal growth data with good handling of missing
values, linear mixed-effects models were used to relate the
continuous growth outcome variables (weight, height and
skinfold thickness) to visit time point, cohort group, and their
interaction with infant age, taking into account the same con-
founders as in the linear regression models for birth measure-
ments. Due to non-linear relationships with age (indicated by
significant estimates for age-squared), time was modelled
using linear splines with knots at ages 3 and 12 months.
Models were fitted to the data by restricted maximum likeli-
hood (REML).
Statistical analyses were conducted using SPSS (IBM
SPSS Statistics for Windows, version 25.0; IBM, Armonk,
New York, USA) and R (version 3.3.2; R Foundation for
Statistical Computing, Vienna, Austria). p < 0.05 was consid-
ered statistically significant.
Results
Women and pregnancy data Table 1 shows the demographics
of the women who participated in the study: 876 control, 98
earlier GDM and 122 recent GDM. Compared with the con-
trol group, women from the earlier GDM cohort had similar
height, ethnicity and IMD levels. In contrast, women in the
recent GDM cohort were shorter, more ethnically diverse,
delivered at an earlier gestational age and were more deprived
(with a higher IMD). Both GDM groups had higher BMI and
increased smoking rate, compared with the control group.
Recent GDM women were also significantly different from
earlier GDM women: they were shorter, delivered at an earlier
gestational age, were more likely to have primiparous pregnan-
cies, and had lower fasting but higher OGTT 60 min venous
glucose concentrations.
Infants’ anthropometric data Earlier OGDMwere significant-
ly heavier at birth (Table 1), as expected, even after further
adjustment for all covariates (Table 2, p = 0.01). Fully adjust-
ed birthweight and adiposity of earlier OGDM were signifi-
cantly greater than those of recent OGDM (Table 2).
After birth, earlier OGDM showed significant downwards
growth trajectories in weight and length between 3 and
12 months compared with control infants (Fig. 1, Table 3).
Between 12 and 24months, weight, height and skinfold thick-
ness of earlier OGDM followed a comparable growth trajec-
tory to control infants. However, at all time points, earlier
OGDM maintained slightly higher mean skinfold thickness
compared with control infants.
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Table 1 Maternal demographics, offspring birth characteristics and cross-sectional comparisons of infant growth variables
Control (N = 876) Recent OGDM (N = 122) Earlier OGDM (N = 98)
Maternal demographics
Age at birth (years) 33.4 ± 4.2 33.6 ± 5.1 33.4 ± 4.4
White 96% 76%* 98%
IMD 8.9 ± 3.3 11.3 ± 6.8** 9.1 ± 3.6
Primiparous pregnancy 48% 52% 37%*
Height (cm) 166.1 ± 7.2 162.7 ± 6.8** 165.8 ± 6.9
Pre-pregnancy BMI (kg/m2) 24.0 ± 4.4 27.0 ± 6.3** 26.6 ± 5.6**
OGTT gestational age (weeks) 28.5 ± 0.7 28.9 ± 5.6 28.5 ± 1.5
Fasting venous glucose (mmol/l) 4.2 ± 0.3 4.8 ± 0.8** 5.3 ± 1.1**
60 min venous glucose (mmol/l) 6.5 ± 1.4 10.6 ± 1.5** 9.2 ± 2.1**
120 min venous glucose (mmol/l) 6.0 ± 1.0 8.5 ± 1.6** 6.7 ± 1.9**
Smoking during pregnancy 3.8% 9.4%* 8.2%*
Offspring birth characteristics
Gestational age (weeks) 40.0 ± 1.3 38.9 ± 0.9** 39.5 ± 1.4**
Caesarean delivery 28% 42%** 40%*
Male infant sex 52% 54% 53%
Weight (kg) 3.523 ± 0.481 3.303 ± 0.472** 3.632 ± 0.588
Weight SDSa 0.07 ± 0.93 0.10 ± 1.01 0.55 ± 1.13**
Length (cm) 51.5 ± 2.4 50.0 ± 2.0** 51.3 ± 2.7
Length SDSa −0.05 ± 0.93 −0.07 ± 0.94 0.22 ± 0.97*
Ponderal index (kg/m3) 25.9 ± 3.2 26.3 ± 2.7 26.7 ± 3.2
Sum of skinfolds (mm) 24.6 ± 6.0 20.0 ± 3.6** 26.0 ± 6.3
Mean skinfold thickness SDSa 0.03 ± 0.86 −0.41 ± 0.61** 0.31 ± 0.85*
Macrosomia (birthweight >4.0 kg) 15% 7%* 27%**
SGA (birthweight <−1.5 SDS) 5% 4% 2%
Cross-sectional infant growth comparisons
3 months Total n = 710 Total n= 102 Total n = 91
Nutrition (exclusively breastfed) 45% 46% 38%
Weight SDSa −0.05 ± 1.03 0.18 ± 1.04 0.29 ± 1.02
Length SDSa 0.14 ± 0.94 −0.03 ± 0.98 0.34 ± 0.96
Mean skinfold thickness SDSa −0.01 ± 0.81 −0.07 ± 0.65 0.04 ± 0.78
12 months Total n = 624 Total n = 86 Total n = 77
Weight SDSa 0.08 ± 1.07 −0.25 ± 1.26** 0.16 ± 1.00
Length SDSa 0.36 ± 1.09 −0.01 ± 1.07 0.31 ± 0.98
Mean skinfold thickness SDSa 0.02 ± 0.78 −0.36 ± 0.74** 0.21 ± 0.69
24 months Total n = 611 Total n = 83 Total n = 76
Weight SDSa 0.19 ± 1.04 −0.03 ± 1.10 0.36 ± 0.96
Length SDSa 0.43 ± 1.05 0.34 ± 1.11 0.42 ± 1.11
Mean skinfold thickness SDSa 0.02 ± 0.83 −0.31 ± 0.65** 0.19 ± 0.64
Values are mean ± SD, or %
Weight-, length- and mean skinfold thickness SDS values are adjusted for gestational age, sex and postnatal age at measurement
Note: in control population, number of participants for length and skinfold thickness measurements at birth is 573
Cross-sectional infant growth comparisons are adjusted for sex, postnatal age at measurement, pre-pregnancy maternal BMI, maternal height (for length
only), parity and 0–3 months feeding history. Comparisons at age 3 months are additionally adjusted for gestational age at birth
a SDS for weight and length are calculated using the UK 1990 reference, for skinfold thickness using internal references
*p < 0.05 vs control group
**p < 0.005 vs control group
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Fig. 1 (a–f) Weight, length/
height and skinfold thickness
growth trajectories of recent or
earlier OGDM compared with
control infants from birth to
2 years. Plotted values are mean ±
SEM, adjusted for sex, gestational
age (birth and 3months only), and
age at measurement.
Comparisons are adjusted for sex,
postnatal age at measurement,
pre-pregnancy maternal BMI,
maternal height (for length/height
only), parity, feeding history at 0–
3 months, delivery method,
maternal ethnicity,
socioeconomic status reflected by
IMD and pregnancy smoking
history. Comparisons between
0 months and 3 months are
additionally adjusted for
gestational age at birth.
Horizontal bars indicate
statistically significant differences
between OGDM and control
groups for the displayed growth
periods (* and dashed bar:
p < 0.05; ** and solid bar:
p < 0.001). Significance is based
on linear mixed-effect models of
infant growth variables between
groups, with time modelled using
linear splines (Table 3)
Table 2 Linear regression com-
parison of infant growth variables
at birth between groups
Outcomes Recent OGDM vs
controls (controls as
reference)
Earlier OGDM vs
controls (controls as
reference)
Recent vs earlier OGDM
β ± SE p β ± SE p p
Weight SDS Model 1 −0.11 ± 0.09 0.24 0.21 ± 0.05 <0.0001 0.001
Model 2 −0.05 ± 0.1 0.629 0.16 ± 0.05 0.002 0.01
Length SDS Model 1 −0.01 ± 0.11 0.925 0.08 ± 0.06 0.192 0.157
Model 2 −0.11 ± 0.11 0.306 0.05 ± 0.06 0.347 0.567
Skinfold SDS Model 1 −0.51 ± 0.09 <0.0001 0.07 ± 0.05 0.167 <0.0001
Model 2 −0.53 ± 0.09 <0.0001 0.05 ± 0.05 0.385 <0.0001
β (regression coefficients) ± SE are displayed
Model 1: adjusted for gestational age (birth and 3 months growth outcomes only), sex and age at measurement
Model 2: Model 1 + adjusted for pre-pregnancy maternal BMI, maternal height (for height gain only), parity
(primiparous, yes/no), feeding history (exclusively breastfed at 3 months, yes/no; except for birth anthropometry),
maternal ethnicity (white, yes/no), IMD, delivery method (Caesarean delivery, yes/no), maternal smoking history
during pregnancy (yes/no)
Skinfold, skinfold thickness
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In contrast, recent OGDM had similar birthweight and
length to control infants, but lower adiposity (skinfold thick-
ness SDS β ± SE: −0.53 ± 0.09, fully adjusted model,
p < 0.0001) (Table 2). All individual skinfolds were signifi-
cantly lower but triceps, flank and quadriceps skinfold thick-
ness were particularly reduced (electronic supplementary ma-
terial [ESM] Table 1).
After birth, recent OGDM showed different growth trajec-
tories to the earlier OGDM and the control group. From birth
to 3 months, weight and skinfold thickness gains were signif-
icantly increased compared with those of control infants and
earlier OGDM, but with reduced length gain compared with
the control group (Fig. 1, Table 3). This was followed by
reduced gains in weight, length and adiposity between 3 and
12 months, compared with control infants (Fig. 1, Table 3).
Weight and length SDS for recent OGDM became compara-
ble with that of control infants only at 24 months, reflecting
increased growth between 12 and 24 months. However, their
skinfold thickness remained lower than that of control infants
even at 24 months (Fig. 1).
Discussion
This observational study demonstrates significant differences
in both birth size and subsequent infancy growth trajectories
between recent and earlier OGDM compared with control
infants. Recent OGDM had comparable birthweight and
length SDS, but unexpectedly reduced skinfold thickness,
indicating lower adiposity, compared with control infants.
Conversely, earlier OGDM were heavier at birth, consistent
with the traditional description of OGDM [1, 2].
Some recent studies concur with our findings. An
Australian study (2013) [10] found no significant difference
Table 3 Linear mixed-effect models of infant growth variables between groups
Outcomes Recent OGDM vs controls (controls as
reference)
Earlier OGDM vs controls (controls as
reference)
Recent vs earlier OGDM
Estimate±SE p Estimate±SE p p
Change 0–3 months
Weight SDS Model 1 0.07 ± 0.03 0.03 −0.05 ± 0.04 0.18 0.0096
Model 2 0.07 ± 0.03 0.039 −0.05 ± 0.04 0.172 0.01
Length SDS Model 1 −0.06 ± 0.03 0.04 −0.03 ± 0.03 0.372 0.477
Model 2 −0.06 ± 0.03 0.035 −0.03 ± 0.04 0.36 0.467
Skinfold SDS Model 1 0.14 ± 0.03 1.37 × 10−5 −0.04 ± 0.04 0.277 8.43 × 10−5
Model 2 0.14 ± 0.03 1.54 × 10−5 −0.05 ± 0.04 0.235 6.45 × 10−5
Change 3–12 months
Weight SDS Model 1 −0.06 ± 0.01 1.39 × 10−7 −0.03 ± 0.01 0.01 0.06
Model 2 −0.06 ± 0.01 1.42 × 10−7 −0.03 ± 0.01 0.01 0.057
Length SDS Model 1 −0.03 ± 0.01 0.004 −0.03 ± 0.01 0.009 0.943
Model 2 −0.03 ± 0.01 0.005 −0.03 ± 0.01 0.01 0.969
Skinfold SDS Model 1 −0.03 ± 0.01 0.009 0.02 ± 0.01 0.15 0.0025
Model 2 −0.03 ± 0.02 0.008 0.02 ± 0.01 0.146 0.002
Change 12–24 months
Weight SDS Model 1 0.015 ± 0.01 0.123 0.003 ± 0.01 0.768 0.368
Model 2 0.01 ± 0.01 0.127 0.003 ± 0.01 0.79 0.361
Length SDS Model 1 0.029 ± 0.005 2.78 × 10−5 0.004 ± 0.01 0.638 0.007
Model 2 0.035 ± 0.008 2.95 × 10−5 0.004 ± 0.009 0.688 0.006
Skinfold SDS Model 1 0.004 ± 0.01 0.638 −0.005 ± 0.01 0.602 0.455
Model 2 0.004 ± 0.01 0.649 −0.006 ± 0.01 0.578 0.446
Fixed effect estimates (visit period and group interaction) ± SE are displayed
Smoothing splines were added to the models with knots at 3 and 12 months
Model 1: adjusted for gestational age (birth and 3 months growth outcomes only), sex and age at measurement
Model 2: Model 1 + adjusted for pre-pregnancy maternal BMI, maternal height (for height gain only), parity (primiparous, yes/no), feeding history
(exclusively breastfed at 3 months, yes/no; except for birth anthropometry), maternal ethnicity (white, yes/no), IMD, delivery method (Caesarean
delivery, yes/no), maternal smoking history during pregnancy (yes/no)
Skinfold, skinfold thickness
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between recent OGDM and control infants’ birthweights; and
a UK study (2016) [11] reported lower weights and lengths for
OGDM vs control infants at 2 weeks of life. Recent GDM
trials (no treatment vs lifestyle advice +/− insulin) also suggest
a shift towards the normal population distribution of
birthweights in OGDM [16, 17].
Reduced subcutaneous fat at birth in our recent OGDM
may be a novel finding. Au et al [10] demonstrated lower
body fat percentage in OGDM at birth, (7.9 ± 4.5% vs 9.5 ±
4.3% in the control group), but this was not statistically sig-
nificant in their relatively small study (N = 67) [24].
Conversely, a recent systematic review and meta-analysis
published in 2017 concluded that newborn adiposity is still
increased in OGDM [25]. However, although the overall num-
bers in that analysis were large, individual studies were small,
and many combined type 1 diabetes, type 2 diabetes and
GDM. Two of the most recent studies showed no body fat
percentage difference between OGDM and control infants
[26, 27]. Logan et al [11] found no difference in total adipose
tissue mass on MRI in OGDM compared with control infants
at 11 days of age. Therefore, our study and recent literature
suggest that GDM diagnosed and treated over the last decade
may result in offspring birthweight and length comparable
with the general population, and even reduced adiposity.
Our recent OGDM cohort showed significantly increased
weight and skinfold thickness gains comparedwith the control
group from birth to 3 months, despite similar breastfeeding
rates. A comparable UK cohort (2011–2014) also found great-
er weight and adiposity gains from birth to 2.5 months in
OGDM [11]. However, in contrast with our findings, their
OGDM cohort still had greater total adipose tissue at
2.5 months, adjusting for sex and maternal pre-pregnancy
BMI [11]. Our recent OGDM then showed reduced gains in
weight and skinfold thickness from 3 to 12 months, resulting
in significantly reduced weight and adiposity at 12 months
compared with control infants. Subcutaneous adiposity in this
group remained lower than in the control group until
24 months of age. In contrast, earlier macrosomic OGDM
showed expected catch-down growth, with slightly reduced
weight and skinfold thickness gains from birth to 3 months,
and significantly decreased gains in weight and length be-
tween 3 and 12 months, compared with control infants.
However, they still had higher adiposity than control infants
at all time points.
The smaller birth size seen in recent OGDM was evident
despite higher maternal BMI and higher OGTT 60 min glu-
cose concentrations compared with earlier OGDM. Both
groups were retrospectively defined using the IADPSG
criteria. Therefore the normalisation of birth anthropometry
seen in recent OGDM is probably due to intensification of
GDM monitoring and treatment, rather than inclusion of indi-
viduals with ‘milder’ GDM. We hypothesise that this could
result from tighter glycaemic control per se, direct effects of
medication transported across the placenta, or interactions be-
tween these environmental factors, genetic predisposition and
epigenetic modulation. Conversely, earlier OGDM showed
predicted increased birthweight, due presumably to greater
nutrient supply in pregnancy and fetal hyperinsulinism. A
weakness of our study is that we do not have uniform data
on glucose variability, maternal treatments and HbA1c to fur-
ther inform this debate.
Amelioration of the classic macrosomic phenotype is likely
to be associated with fewer adverse outcomes; however, the
long-term effect of early reduced infancy weight and subcuta-
neous fat could be associated with risk itself, particularly if
leading to catch-up growth, which has been associated with
risk for childhood obesity and adult type 2 diabetes [18, 28].
The finding that tight glucose control can not only normalise
birthweight but also be associated with reduced body size has
been previously reported. Langer et al investigated three
GDM groups and showed that the group with lowest maternal
glucose values had a higher proportion of small for gestational
age (SGA) infants [29]. The timing of treatment could also
play a role as a recent study reported that early GDM treatment
was associated with a higher rate of SGA-related neonatal
intensive care unit admissions, whereas later treatment result-
ed in more large for gestational age infants [30]. The recent
HAPO data relating to the follow-up of infants born to
mothers with a wide range of glucose values at 28 weeks
gestation confirm a positive relationship between those levels
and adiposity at 10–14 years (skinfold thickness and air dis-
placement plethysmography) [31]. As well as linking high
antenatal glucose exposures to childhood overweight/obesity,
we could also infer from these data that lower glucose expo-
sures might result in persisting reduced adiposity. Therefore,
while there are clear advantages of intensive multidisciplinary
GDM management, there may also be negative implications
for some OGDM.
In addition to more extensive diet and lifestyle advice,
medical treatment of GDM has changed significantly over
recent years [11]. Metformin is now commonly used world-
wide, often as first-line medication, and crosses the placenta in
significant amounts. While we were unable to include medi-
cation use in our analyses, 20% of women were treated with
metformin (+/− insulin) during recent GDM recruitment,
compared with near zero for the earlier GDM (clinic data).
We therefore postulate that metformin itself may at least partly
explain the differences seen between recent and earlier
OGDM anthropometry and growth trajectories. The
Metformin in Gestational Diabetes (MiG) trial, randomising
women with GDM to metformin (+/− insulin if needed) or
insulin, suggested that metformin might affect infancy fat de-
position patterns. There were no differences at birth [32].
However, at 2 years of age, children from themetformin group
had increased subscapular and biceps skinfold thickness, de-
spite no difference in overall fat, suggesting a more favourable
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fat distribution [32]. Our recent OGDM cohort with greater
metformin exposure, compared with the earlier group, shows
preferentially increased gains in 3 month subscapular skinfold
thickness and then reduced gains until 2 years of age (ESM
Table 1).
At 7–9 years, OGDM randomised to metformin in theMiG
trial had similar total body fat and metabolic measures, al-
though the 9 year olds were larger [33]. A study in polycystic
ovary syndrome (PCOS) suggested a growth restriction effect
of metformin in infants of normal-weight mothers [34]. It is
therefore hard to interpret whether metformin may confer a
beneficial fat distribution or an increased long-term risk of
obesity. Metformin effects may also differ depending on ma-
ternal weight gain, glycaemic control and other environmental
factors. Further studies are needed to elucidate the effect of
metformin itself, effects on maternal energy intake and weight
gain, and interactions with other environmental factors, on
adiposity distribution.
To our knowledge, no previous study has investigated
growth trajectories of recent OGDM, in comparison with a
control group, up to 24 months of age. Strengths of this study
includemeasures of length and skinfold thickness adiposity, in
addition to weight, in a large cohort. Collection of detailed
maternal and demographic data allowed adjustment for poten-
tial confounding factors. Use of the IADPSG diagnostic
criteria [12] means that our results are relevant to populations
worldwide, where GDM is now diagnosed using lower thresh-
olds and is more aggressively treated. The ‘recent’ OGDM
cohort showed a slightly increased prevalence of ethnic mi-
nority groups. However, ethnicity was not a significant covar-
iate in our growth models. Local hospital demographic data
(not shown) for all GDM mother–infant dyads born at the
same time as the recent group were similar to the study pop-
ulation, and therefore anthropometric findings of recent
OGDM at birth were unlikely to result from study participa-
tion bias. Furthermore, the anthropometric measures for more
recent control participants recruited in Cambridge have not
shown any evidence of a secular trend in infancy growth (data
not shown).
Limitations of the study include that the two OGDM
groups are not fully comparable, and no details are available
of glycaemic control after GDM diagnosis, although it is like-
ly that more intensive treatment of recent GDMwomen led to
tighter glycaemic control. Since data regarding weight gain
during pregnancy were incomplete, it cannot be confirmed
that recent GDM women had adequate pregnancy weight
gain. The study population was large compared with most
previous studies; however, there were insufficient numbers
to investigate the individual effects of metformin and insulin
on anthropometric outcomes. A further limitation is that 19%
of women in the earlier cohort were identified retrospectively
and did not receive GDM treatment. However, excluding
these women would still give similar outcomes in the
regression models (ESM Table 2). Studies are needed to fur-
ther understand the mechanisms responsible for anthropomet-
ric outcomes in OGDM, and ideal GDM treatment going for-
ward. We believe that the trend has been towards stricter ap-
plication of ‘targets’ blood testing and the greater use of met-
formin. Aweakness of our study is that we do not have accu-
rate details of glucose concentrations, HbA1c or metformin
use in these populations. Going forward, continuous glucose
monitoring data defining individual glucose exposures may
clarify these factors. Our work and that of others suggests that
it will be informative to further study adiposity distribution in
OGDM, including subcutaneous and visceral fat deposits, to
investigate beneficial vs undesirable adiposity gains.
It is debatable whether reduced early anthropometric mea-
sures in OGDM will have positive or negative implications,
particularly for longer-term health. In the neonatal period it
may be advantageous, allowing normal birthweights and re-
duced pregnancy complications. However, this could result in
increased numbers of SGA infants, and associated comorbid-
ities. Reduced size at birth, leading to subsequent early catch-
up growth, may also lead to later increased metabolic disease
risk [35].
Conclusion
We hypothesise that recent changes in the detection and inten-
sive multidisciplinary management of GDM, with dietary and
lifestyle modifications, and medication where needed, has im-
proved glycaemic control resulting in a birth size similar to
control infants. The normalisation of birthweight, compared
with earlier OGDM, may be associated with improved later-
life metabolic health [36]. However, our findings and those of
others show subsequent increased anthropometric gains, akin
to postnatal catch-up growth in SGA babies, which may con-
vey its own metabolic risks [28]. It may be that there will be a
trade-off between tighter glycaemic control, direct effects of
medication, birth size and infancy growth trajectories. This
cohort continues to be followed up and later childhood data
will be of interest, as well as replication in other populations.
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